Final report of the OLYMPUS Jelmyto trial: Takeaways for urologists

In this video, Seth P. Lerner, MD, gives the final results of the phase 3 OLYMPUS trial, which studied the efficacy of mitomycin-containing reverse thermal gel (UGN-101; Jelmyto) in patients with upper tract urothelial carcinoma and supported the FDA approval of the treatment in this setting.

Lerner is a professor in the Scott Department of Urology and Beth and Dave Swalm Chair in urologic oncology at the Baylor College of Medicine Medical Center in Houston, Texas.